Monica S Thakar
Overview
Explore the profile of Monica S Thakar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1461
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cox E, Summers C, Milano F, Dahlberg A, Bleakley M, Sandmaier B, et al.
Ann Hematol
. 2024 Jul;
103(9):3737-3743.
PMID: 39003390
With advancements in novel therapeutics, it is unclear whether third hematopoietic cell transplantation (HCT3) has a place in the treatment of recurrent hematopoietic malignancies. We evaluated patients with hematologic malignancies...
2.
Kim S, Nordlander A, Xie H, Kim Y, Ogimi C, Thakar M, et al.
Clin Infect Dis
. 2024 Apr;
79(3):761-771.
PMID: 38666501
Background: Pretransplant respiratory virus (RV) infections have been associated with negative transplant outcomes in adult hematopoietic cell transplantation (HCT) recipients. In the era of HCT delay because of high-risk RVs,...
3.
Thakar M, Sorror M
Hematology Am Soc Hematol Educ Program
. 2023 Dec;
2023(1):731-736.
PMID: 38066934
A 3-year-old child with chronic granulomatous disease was brought to the transplant clinic by his parents. The patient has a history of Aspergillus fumigatus pneumonia, which required mechanical ventilation, and...
4.
Eissa H, Thakar M, Shah A, Logan B, Griffith L, Dong H, et al.
J Allergy Clin Immunol
. 2023 Oct;
153(1):287-296.
PMID: 37793572
Background: The Primary Immune Deficiency Treatment Consortium (PIDTC) enrolled children in the United States and Canada onto a retrospective multicenter natural history study of hematopoietic cell transplantation (HCT). Objective: We...
5.
Thakar M, Logan B, Puck J, Dunn E, Buckley R, Cowan M, et al.
Lancet
. 2023 Jun;
402(10396):129-140.
PMID: 37352885
Background: Severe combined immunodeficiency (SCID) is fatal unless durable adaptive immunity is established, most commonly through allogeneic haematopoietic cell transplantation (HCT). The Primary Immune Deficiency Treatment Consortium (PIDTC) explored factors...
6.
Patel N, Torgerson T, Thakar M, Younger M, Sriaroon P, Pozos T, et al.
J Clin Immunol
. 2023 Jun;
43(7):1557-1565.
PMID: 37266769
Primary immunodeficiency disease (PIDD) comprises a group of disorders of immune function. Some of the most severe PIDD can be treated with hematopoietic cell transplant (HCT). Hizentra® is a 20%...
7.
Dvorak C, Haddad E, Heimall J, Dunn E, Cowan M, Pai S, et al.
J Allergy Clin Immunol
. 2022 Dec;
151(2):547-555.e5.
PMID: 36456360
Background: Shearer et al in 2014 articulated well-defined criteria for the diagnosis and classification of severe combined immunodeficiency (SCID) as part of the Primary Immune Deficiency Treatment Consortium's (PIDTC's) prospective...
8.
Friend B, Broglie L, Logan B, Chhabra S, Bupp C, Schiller G, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):123.e1-123.e10.
PMID: 36442769
Allogeneic hematopoietic cell transplantation is a curative procedure for hematologic malignancies but is associated with a significant risk of non-relapse mortality (NRM). The Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) is a...
9.
Broglie L, Friend B, Chhabra S, Logan B, Bupp C, Schiller G, et al.
Transplant Cell Ther
. 2022 Nov;
29(2):125.e1-125.e9.
PMID: 36442768
Allogeneic hematopoietic cell transplantation (HCT) can cure many nonmalignant conditions, but concern for morbidity and mortality remains. To help physicians estimate patient-specific transplant mortality risk, the HCT comorbidity index (HCT-CI)...
10.
Cuvelier G, Logan B, Prockop S, Buckley R, Kuo C, Griffith L, et al.
Blood
. 2022 Jun;
140(7):685-705.
PMID: 35671392
Adenosine deaminase (ADA) deficiency causes ∼13% of cases of severe combined immune deficiency (SCID). Treatments include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (GT). We evaluated...